{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:46:47Z","timestamp":1783518407460,"version":"3.55.0"},"reference-count":30,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.3892\/etm.2015.2549","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T09:37:12Z","timestamp":1433497032000},"page":"519-524","source":"Crossref","is-referenced-by-count":34,"title":["Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis"],"prefix":"10.3892","volume":"10","author":[{"given":"HIROSHI","family":"CHANTAPHAKUL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"THANOMSAK","family":"SANON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JETTANONG","family":"KLAEWSONGKRAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,6,5]]},"reference":[{"key":"key20180108124319_b1-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"key20180108124319_b2-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/CCM.0b013e31821201ed","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review","volume":"39","author":"Gerull","year":"2011","journal-title":"Crit Care Med"},{"key":"key20180108124319_b3-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00128071-200607010-00004","article-title":"Cutaneous fungal infections in the oncology patient: Recognition and management","volume":"7","author":"Mays","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"key20180108124319_b4-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0891-5520(20)30615-2","article-title":"Dermatologic manifestations of infections in neutropenic patients","volume":"8","author":"Bodey","year":"1994","journal-title":"Infect Dis Clin North Am"},{"key":"key20180108124319_b5-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02113442","article-title":"Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection","volume":"14","author":"Fournier","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key20180108124319_b6-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/1346-8138.12136","article-title":"Adult case of Stevens-Johnson syndrome possibly induced by Chlamydophila pneumoniae infection with severe involvement of bronchial epithelium resulting in constructive respiratory disorder","volume":"40","author":"Tanaka","year":"2013","journal-title":"J Dermatol"},{"key":"key20180108124319_b7-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"e2011004","DOI":"10.4084\/mjhid.2011.004","article-title":"Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis","volume":"3","author":"Khalaf","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"key20180108124319_b8-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hcs078","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: A 3-year prospective study","volume":"105","author":"Kannenberg","year":"2012","journal-title":"QJM"},{"key":"key20180108124319_b9-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaip.2013.11.005","article-title":"Fever, rash and systemic symptoms: Understanding the role of virus and HLA in severe cutaneous drug allergy","volume":"2","author":"Pavlos","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"key20180108124319_b10-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s001340051056","article-title":"Skin lesions in the ICU","volume":"25","author":"Badia","year":"1999","journal-title":"Intensive Care Med"},{"key":"key20180108124319_b11-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bjps.2004.04.025","article-title":"Lyell syndrome revisited: Analysis of 18 cases of severe bullous skin disease in a burns unit","volume":"58","author":"Neff","year":"2005","journal-title":"Br J Plast Surg"},{"key":"key20180108124319_b12-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome and toxic epidermal necrolysis in Germany (1990\u20131992): Structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"key20180108124319_b13-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key20180108124319_b14-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: A severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"key20180108124319_b15-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2012.04.002","article-title":"Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis","volume":"66","author":"Chung","year":"2012","journal-title":"J Dermatol Sci"},{"key":"key20180108124319_b16-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/ACI.0000000000000076","article-title":"The study of severe cutaneous drug hypersensitivity reactions from a systems biology perspective","volume":"14","author":"Perkins","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"key20180108124319_b17-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"key20180108124319_b18-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180108124319_b19-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180108124319_b20-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"key20180108124319_b21-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"key20180108124319_b22-etm-0-0-2549","first-page":"142","article-title":"Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy","volume":"7","author":"Mockenhaupt","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"key20180108124319_b23-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key20180108124319_b24-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ophtha.2010.06.035","article-title":"Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis","volume":"118","author":"L\u00f3pez-Garcia","year":"2011","journal-title":"Ophthalmology"},{"key":"key20180108124319_b25-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/bjo.2006.109124","article-title":"The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy","volume":"91","author":"De Rojas","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key20180108124319_b26-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/jop.2012.0009","article-title":"Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye","volume":"29","author":"Prabhasawat","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"key20180108124319_b27-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1365-2133.2007.08222.x","article-title":"Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN","volume":"157","author":"Hague","year":"2007","journal-title":"Br J Dermatol"},{"key":"key20180108124319_b28-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5415\/apallergy.2013.3.4.215","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: An Asia-pacific perspective","volume":"3","author":"Thong","year":"2013","journal-title":"Asia Pac Allergy"},{"key":"key20180108124319_b29-etm-0-0-2549","first-page":"e35","article-title":"Are multimorbidities underestimated in scoring systems of Stevens-Johnson syndrome and toxic epidermal necrolysis like in SCORTEN","volume":"12","author":"von Wild","year":"2012","journal-title":"Eplasty"},{"key":"key20180108124319_b30-etm-0-0-2549","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.2012.11074.x","article-title":"The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies","volume":"167","author":"Lee","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2015.2549\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T07:29:39Z","timestamp":1652254179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2015.2549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,5]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,6,5]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.3892\/etm.2015.2549"],"URL":"https:\/\/doi.org\/10.3892\/etm.2015.2549","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,5]]}}}